AUTL
Autolus Therapeutics plc
$1.55
+$0.04(+2.65%)
37
Overall
60
Value
10
Tech
42
Quality
Market Cap
$409.86M
Volume
1.50M
52W Range
$1.11 - $4.12
Target Price
$9.59
Order:
Income Statement
| Metric | Trend | Chart | 2018 Sep | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||
| Total Revenue | $1.4M | $2.9M | $1.7M | $2.3M | $6.4M | $1.7M | $10.1M | ||
| Total Revenue | $1.4M | $2.9M | $1.5M | $1.5M | $6.2M | $1.7M | $10.1M | ||
| COST OF GOODS SOLD | |||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $11.4M | ||
| GROSS PROFIT | |||||||||
| Gross Profit | $1.4M | $2.9M | $1.7M | $1.5M | $6.2M | $1.7M | $-1.3M | ||
| OPERATING EXPENSES | |||||||||
| Operating Expenses | $-57.5M | $144.9M | $169.9M | $166.7M | $149.1M | $177.2M | $239.5M | ||
| Research & Development | $36.1M | $105.4M | $134.9M | $134.8M | $117.4M | $130.5M | $138.4M | ||
| Research Expense | $36.1M | $105.4M | $134.9M | $134.8M | $117.4M | $130.5M | $138.4M | ||
| Selling, General & Administrative | $22.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | $101.1M | ||
| General & Administrative Expenses | $22.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | $101.1M | ||
| Salaries & Wages | $-6.8M | $-30.4M | $-20.0M | -- | -- | $11.2M | $15.5M | ||
| Depreciation & Amortization | $-1.7M | $-4.6M | $-5.7M | $8.6M | $7.3M | $6.6M | $7.6M | ||
| Depreciation & Amortization | $-1.7M | $-4.6M | $-5.7M | $8.6M | $7.3M | $6.6M | $7.6M | ||
| Amortization | -- | $-47.0M | $-91.0K | $90.0K | $65.0K | -- | $1.1M | ||
| Other Operating Expenses | -- | -- | -- | $7.5M | $5.9M | $9.3M | $10.6M | ||
| OPERATING INCOME | |||||||||
| Operating income | $-57.5M | $-144.9M | $-168.1M | $-165.0M | $-143.4M | $-179.7M | $-241.4M | ||
| EBITDA | $-50.3M | $-134.4M | $-160.6M | $-132.5M | $-132.2M | $-156.8M | $-202.1M | ||
| NON-OPERATING ITEMS | |||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | $1.1M | $8.9M | $45.1M | $9.3M | ||
| Intinc | $1.5M | $2.5M | $536.0K | $262.0K | $1.7M | $13.5M | $32.4M | ||
| Net Non-Operating Interest Income/Expense | $1.5M | $2.5M | $536.0K | $-843.0K | $-7.2M | $13.5M | $32.4M | ||
| Gain on Sale of Securities | -- | -- | $160.0K | -- | -- | -- | -- | ||
| Other Income/Expense | $-4.0M | $-7.4M | $-1.4M | $821.0K | $1.5M | $4.0M | $417.0K | ||
| Other Special Charges | $4.0M | $7.4M | $1.4M | $-145.0K | $2.0M | $222.0K | $220.0K | ||
| SPECIAL ITEMS | |||||||||
| Special Income Charges | $10.0K | $-4.1M | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | $-10.0K | $4.1M | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | |||||||||
| EBIT | $-52.0M | $-139.0M | $-166.3M | $-140.9M | $-139.7M | $-163.3M | $-209.8M | ||
| Pre-Tax Income | $-52.0M | $-139.0M | $-166.3M | $-166.0M | $-148.6M | $-208.4M | $-219.1M | ||
| INCOME TAX | |||||||||
| Tax Provision | $-7.3M | $-15.2M | $-24.2M | $58.0K | $272.0K | $-19.0K | $1.5M | ||
| NET INCOME | |||||||||
| Net Income | $-44.7M | $-123.8M | $-142.1M | $-142.1M | $-148.8M | $-208.4M | $-220.7M | ||
| Net Income (Continuing Operations) | $-44.7M | $-123.8M | $-142.1M | $-142.1M | $-148.8M | $-208.4M | $-220.7M | ||
| Net Income (Discontinued Operations) | $-44.7M | $-123.8M | $-142.1M | $-142.1M | $-148.8M | $-208.4M | $-220.7M | ||
| Net Income (Common Stockholders) | $-44.7M | $-123.8M | $-142.1M | $-142.1M | $-148.8M | $-208.4M | $-220.7M | ||
| TOTALS | |||||||||
| Total Expenses | $-57.5M | $144.9M | $169.9M | $166.7M | $149.1M | $177.2M | $250.9M | ||
| SHARE & EPS DATA | |||||||||
| Average Shares Outstanding | $31.6M | $43.1M | $51.6M | $72.1M | $95.0M | $173.9M | $255.2M | ||
| Average Shares Outstanding (Diluted) | $31.5M | $43.0M | $51.5M | $72.1M | $95.0M | $173.9M | $255.2M | ||
| Shares Outstanding | $40.1M | $45.0M | $52.3M | $90.9M | $173.1M | $266.1M | $266.1M | ||
| Basic EPS | -- | -- | $-2.76 | $-1.97 | $-1.57 | $-1.2 | $-0.86 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | $-1.97 | $-1.57 | $-1.2 | $-0.86 | ||
| Diluted EPS | $-1.42 | $-2.88 | $-2.76 | $-1.97 | $-1.57 | $-1.2 | $-0.86 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | $-1.97 | $-1.57 | $-1.2 | $-0.86 | ||
| OTHER METRICS | |||||||||
| Gain On Sale Of P P E | -- | -- | -- | $-676.0K | $-515.0K | $-3.8M | $-223.0K | ||
| Other Gand A | $22.8M | $39.5M | $35.0M | $31.9M | $31.9M | $46.7M | $101.1M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | $382.0K | $414.0K | ||
| Rent And Landing Fees | $22.8M | $39.5M | $35.0M | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | AUTL | $1.55 | +2.6% | 1.50M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Autolus Therapeutics plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW